Industry Developments

BMI View: Three main factors govern our outlook for Ukraine's pharmaceutical market in 2012 and 2013: the worsening economic growth prospects, the high potential for devaluation of... 2012-02-01

BMI View: We believe the long-awaited formation of a joint venture (JV) between Actavis and Bioton in the field of insulin production and commercialisation is highly favourable for... 2012-02-01

BMI View: While there has been no immediate impact on Romania's health system following the withdrawal of the draft healthcare reform bill, the development is bad news for private healthcare... 2012-01-16

BMI View: While the Turkish pharmaceutical industry has achieved some concessions following additional price cuts and public discounts announced in November 2011, the impact of the... 2012-01-06

BMI View: Following the BMI Country Risk team's downgrade to Turkey's 2012 macroeconomic projections, BMI's Pharmaceutical and Healthcare team have moderately revised the growth expectations... 2011-12-15

BMI View: Sopharma's successful transition from a domestically focused drugmaker to a substantial exporter of pharmaceuticals to Eastern and South Eastern Europe underlines its potential... 2011-12-13

BMI View: We believe Russia's latest healthcare reform law will act as a further modernising force and, due to late-stage amendments, is broadly positive for the pharmaceutical industry.... 2011-12-12

BMI View: Corrections to the reintroduced claw-back mechanism in Romania are favourable to drugmakers, but the levy itself is still overly burdensome. In October 2011, we stated that:... 2011-12-07

BMI View: It is highly encouraging that the Serbian government has so clearly indicated it is willing to settle the liabilities of public agencies, such as the Serbian National Health... 2011-11-23

BMI View: The Turkish pharmaceutical market has received another blow from the government that considerably decreases its attractiveness to drugmakers and will result in another year... 2011-11-21